Seminal Articles—Soft-Tissue Sarcoma

Based on our expert’s review, here are the must-read articles for every oncologist about soft-tissue sarcoma.

1. Matushansky I, Taub RN. Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma. Nat Rev Clin Oncol. 2011;8(7):434-438.

2. Charytonowicz E, Matushansky I, Castillo-Martin M, et al. Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis. Clin Transl Oncol. 2011;13(3):194-203.

3. Mills J, Hricik T, Siddigi S, Matushansky I. Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. Mol Cancer Ther. 2011;10(2):313-324.

4. Matushansky I, Charytonowicz E, Mills J, Siddigi S, Hricik T, Cordon-CArdo C. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st century. Expert Rev Anticancer Ther. 2009;9(8):1135-1144. Free

5. Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman Ml. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett. 2009;279(2):126-136.

6. Matushansky I, Hernando E, Socci ND, et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol. 2008;172(4):1069-1080. Free

7. Matushansky I, Hernando E, Socci ND, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 2007;117(11):3248-3257. Free

8. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13(6):748-753.

9. Matushansky I, Maki RG. Mechanisms of sarcomagenesis. Hematol Oncol Clin North Am. 2005;19(3):427-449. Elsevier

10. O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235–2241. Elsevier

11. Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol. 2002;25:468–473.

12. Bonvalot S, Cavalcanti A, Le Péchoux C, et al. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur J Surg Oncol. 2005;31:917–923.

13. Mace JR, Keohan ML, Bernardy H, et al. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Can Res. 2003;9:5829–5834. Free

14. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144–3150.

15. Gortzak E, Azzarelli A, Buesa J, et al. A randomized phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–1103. Elsevier

16. Maki RG, Wathen JK, Patel SR, Priebat DA, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25(19):2755-2763.

17. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Fiqueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573. Free